Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 16

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
96,536 262,416 274,571 Spatial35,373 29,668 103,017 85,330 Total consumables revenue127,892 126,204 365,433 359,901 Services8,128 6,299 24,255 17,292 Products and services revenue148,019 151,559 430,999 445,554 License and royalty revenue983 95 45,794 210 Total revenue$149,002 $151,654 $476,793 $445,764 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024AmericasUnited States(1)$77,246 $84,723 $267,555 $250,032 Americas (excluding United States)2,625 3,099 9,044 10,511 Total Americas79,871 87,822 276,599 260,543 Europe, Middle East and Africa41,624 37,851 108,253 109,934 Asia-PacificChina15,189 15,030 55,242 42,692 Asia-Pacific (excluding China)12,318 10,951 36,699 32,595 Total Asia-Pacific27,507 25,981 91,941 75,287 Total revenue$149,002 $151,654 $476,793 $445,764 (1) Includes license and royalty revenue.   License and Royalty RevenueIn February 2025, the Company settled its worldwide patent litigation with Vizgen, Inc. As part of that settlement, Vizgen has limited rights to certain intellectual property owned or exclusively licensed by the Company. As one part of the settlement, the Company received an upfront payment of $26.0 million and will receive royalties on Vizgen’s sales of products covered by the 

14

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

license. The $26.0 million upfront payment was recorded as a $9.2 million gain on settlement and $16.8 million of license and royalty revenue. The amount attributed to the gain on settlement was determined by applying a royalty rate to the Vizgen historical